Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of UCB0942 When Used as Adjunctive Therapy for Partial-onset Seizures in Adult Subjects With Highly Drug-resistant Focal Epilepsy

NCT02625090 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT02625090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02625090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of UCB0942 When Used as Adjunctive Therapy for Partial-onset Seizures in Adult Subjects With Highly Drug-resistant Focal Epilepsy
Lead sponsor
UCB Biopharma SRL
Phase
Phase 2
Overall status
Terminated
Start date
December 3, 2015
Completion date
November 24, 2020
Enrollment
42 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

highly drug-resistant focal epilepsy